The DOI matches its Crossref record; 302 of the 302 references it cites were found in a registry or an index.
Industrial natural product chemistry for drug discovery and development
Abstract
Covering: up to March 2013. In addition to their prominent role in basic biological and chemical research, natural products are a rich source of commercial products for the pharmaceutical and other industries. Industrial natural product chemistry is of fundamental importance for successful product development, as the vast majority (ca. 80%) of commercial drugs derived from natural products require synthetic efforts, either to enable economical access to bulk material, and/or to optimize drug properties through structural modifications. This review aims to illustrate issues on the pathway from lead to product, and how they have been successfully addressed by modern natural product chemistry. It is focused on natural products of current relevance that are, or are intended to be, used as pharmaceuticals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–302 of 302
SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus
Ghosh, R. K., Ghosh, S. M., Chawla, S., & Jasdanwala, S. A. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011400604 · Cited by 88
Artemisinin antimalarials: preserving the “magic bullet”
Maude, R. J., Woodrow, C. J., & White, L. J. (2009) · Drug Development Research · doi:10.1002/ddr.20344 · Cited by 82
Metabolic engineering of artemisinin biosynthesis in Artemisia annua L.
Liu, B., Wang, H., Du, Z., Li, G., & Ye, H. (2010) · Plant Cell Reports · doi:10.1007/s00299-010-0967-9 · Cited by 82
Ensuring sustained ACT production and reliable artemisinin supply
Kindermans, J.-M., Pilloy, J., Olliaro, P., & Gomes, M. F. (2007) · Malaria Journal · doi:10.1186/1475-2875-6-125 · Cited by 81
Litaudon, M., Hart, J. B., Blunt, J. W., Lake, R., & Munro, M. H. G. (1994) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)78563-7 · Cited by 81
From nature to the laboratory and into the clinic
Nicolaou, K. C., Chen, J. S., & Dalby, S. M. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.089 · Cited by 81
Luippold, G., Klein, T., Mark, M., & Grempler, R. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01569.x · Cited by 79
Tetracycline analogs whose primary target is not the bacterial ribosome
Chopra, I. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.637 · Cited by 78
Pharmacokinetic and pharmacodynamic evaluation of tigecycline
Giamarellou, H., & Poulakou, G. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.623126 · Cited by 78
Molecular Contacts Between Antibiotics and the 30S Ribosomal Particle
Wirmer, J., & Westhof, É. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(06)15012-0 · Cited by 77
Effects of SGLT2 inhibitors on cardiovascular outcomes
Foote, C., Perkovic, V., & Neal, B. C. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441190 · Cited by 76
Debono, M., Abbott, B. J., Turner, J. R., Howard, L. C., Gordee, R. S., HUNT, A. S., BARNHART, M., MOLLOY, R. M., Willard, K. E., Fukuda, D. S., et al. (1988) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1988.tb40398.x · Cited by 75
A concise stereoselective total synthesis of (+)-artemisinin
Yadav, J. S., Thirupathaiah, B., & Pabbaraja, S. (2010) · Tetrahedron · doi:10.1016/j.tet.2010.01.051 · Cited by 75
Fluorocyclines. 2. Optimization of the C-9 Side-Chain for Antibacterial Activity and Oral Efficacy
Clark, R. B., Hunt, D. K., He, M., Achorn, C., Chen, C.-L., Deng, Y., Fyfe, C., Grossman, T. H., Hogan, P. C., O’Brien, W. J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201467r · Cited by 74
Glucan synthase inhibitors as antifungal agents
Kurtz, M. B., & Rex, J. H. (2001) · Advances in protein chemistry · doi:10.1016/s0065-3233(01)56011-8 · Cited by 73
Balkovec, J. M., Black, R. M., Hammond, M. L., Heck, J. V., Zambias, R. A., Abruzzo, G. K., Bartizal, K. F., Kropp, H., & Trainor, C. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00079a027 · Cited by 72
The total synthesis of dl-6-demethyl-6-deoxytetracycline
Korst, J. J., Johnston, J. D., Butler, K., Bianco, E. J., Conover, L. H., & Woodward, R. B. (1968) · Journal of the American Chemical Society · doi:10.1021/ja01004a041 · Cited by 72
Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs
Graziani, E. I. (2009) · Natural Product Reports · doi:10.1039/b804602f · Cited by 71
Structurally simplified macrolactone analogues of halichondrin B
Seletsky, B. M., Wang, Y., Hawkins, L. D., Palme, M. H., Habgood, G. J., DiPietro, L., Towle, M. J., Salvato, K. A., Wels, B. F., Aalfs, K. K., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.08.068 · Cited by 71
Discovery of Artemisinin (Qinghaosu)
Liao, F. (2009) · Molecules · doi:10.3390/molecules14125362 · Cited by 71
Masurekar, P. S., Fountoulakis, J., HALLADA, T. C., SOSA, M. S., & KAPLAN, L. (1992) · The Journal of Antibiotics · doi:10.7164/antibiotics.45.1867 · Cited by 71
Dong, C., Henderson, J. A., Kaburagi, Y., Sasaki, T., Kim, D., Kim, J. T., Urabe, D., Guo, H., & Kishi, Y. (2009) · Journal of the American Chemical Society · doi:10.1021/ja9058487 · Cited by 70
Schwartz, S. L., Akinlade, B., Klasen, S., Kowalski, D. L., Zhang, W., & Wilpshaar, W. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0012 · Cited by 70
Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin
Ludueña, R. F., Roach, M. C., Prasad, V., & Pettit, G. R. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90079-c · Cited by 70
Novel GLP-1 receptor agonists for diabetes
Garber, A. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638282 · Cited by 69
The Total Synthesis of 6-Demethyl-6-Deoxytetracycline
Conover, L. H., Butler, K., Johnston, J. D., Korst, J. J., & Woodward, R. B. (1962) · Journal of the American Chemical Society · doi:10.1021/ja00875a063 · Cited by 66
Cellular targets of natural products
Dixon, N., Wong, L. S., Geerlings, T. H., & Micklefield, J. (2007) · Natural Product Reports · doi:10.1039/b616808f · Cited by 66
Ley, S. V., Tackett, M. N., Maddess, M. L., Anderson, J. C., Brennan, P. E., Cappi, M. W., Heer, J. P., Helgen, C., Kori, M., Kouklovsky, C., et al. (2009) · Chemistry - A European Journal · doi:10.1002/chem.200801656 · Cited by 66
Frampton, J. E., & Curran, M. P. (2005) · Drugs · doi:10.2165/00003495-200565180-00008 · Cited by 66
Noorden, R. V. (2010) · Nature · doi:10.1038/466672a · Cited by 63
Natural Product Synthesis: Changes over Time
Hoffmann, R. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203319 · Cited by 63
Tetracyclines. 9. Total synthesis of dl-terramycin
Muxfeldt, H., Haas, G. W., Hardtmann, G. E., Kathawala, F., Mooberry, J. B., & Vedējs, E. (1979) · Journal of the American Chemical Society · doi:10.1021/ja00497a035 · Cited by 63
Present and Future of PI3K Pathway Inhibition in Cancer: Perspectives and Limitations
Ciraolo, E., Morello, F., & Hirsch, E. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796011193 · Cited by 61
Tetracyclines. V.1 A Total Synthesis of (±)-6-Deoxy-6-demethyltetracycline
Muxfeldt, H., & Rogalski, W. (1965) · Journal of the American Chemical Society · doi:10.1021/ja01082a056 · Cited by 61
Targeted Drug Delivery Using Immunoconjugates: Principles and Applications
Pasquetto, M. V., Vecchia, L., Covini, D., Digilio, R., & Scotti, C. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318234ecf5 · Cited by 61
Small molecules targeting phosphoinositide 3-kinases
Wu, P., & Hu, Y. (2012) · MedChemComm · doi:10.1039/c2md20044a · Cited by 60
Debono, M., Abbott, B. J., Fukuda, D. S., BARNHART, M., Willard, K. E., MOLLOY, R. M., Michel, K.-H., Turner, J. R., Butler, T. F., & Hunt, A. H. (1989) · The Journal of Antibiotics · doi:10.7164/antibiotics.42.389 · Cited by 60
The Chemical Biology of Immunophilin Ligands
Gaali, S., Gopalakrishnan, R., Wang, Y., Kozany, C., & Hausch, F. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711798194342 · Cited by 60
Lee, C., Choi, J. W., & Chun, J. J. M. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1008-5 · Cited by 59
Ellsworth, B. A., Meng, W., Patel, M. M., Girotra, R. N., Wu, G., Sher, P. M., Hagan, D. L., Obermeier, M. T., Humphreys, W. G., Robertson, J. G., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.109 · Cited by 58
Binding of tetracycline to the 30S ribosomes and to polyuridylic acid
Connamacher, R. H., & Mandel, H. G. (1965) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(65)90954-x · Cited by 57
Isakoff, S. J., & Baselga, J. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6679 · Cited by 57
Hardman, T. C., & Dubrey, S. W. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0004-1 · Cited by 57
Zambias, R. A., Hammond, M. L., Heck, J. V., et al. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00093a018 · Cited by 56
Maddess, M. L., Tackett, M. N., Watanabe, H., Brennan, P. E., Spilling, C. D., Scott, J. S., Osborn, D. P., & Ley, S. V. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200604053 · Cited by 56
Natural products as catalysts for innovation: a pharmaceutical industry perspective
Schmitt, E. K., Moore, C. M., Krastel, P., & Petersen, F. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.018 · Cited by 55
Veltkamp, S. A., Kadokura, T., Krauwinkel, W. J. J., & Smulders, R. A. (2011) · Clinical Drug Investigation · doi:10.1007/bf03256922 · Cited by 55
Tetracyclines. VII. Total synthesis of dl-terramycin
Muxfeldt, H., Hardtmann, G. E., Kathawala, F., Vedējs, E., & Mooberry, J. B. (1968) · Journal of the American Chemical Society · doi:10.1021/ja01025a063 · Cited by 54
Actions of Gila monster venom on dispersed acini from guinea pig pancreas
Raufman, J., Jensen, R. T., Sutliff, V. E., Pisano, J. J., & Gardner, J. D. (1982) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1982.242.5.g470 · Cited by 53
A practical, convergent route to the key precursor to the tetracycline antibiotics
Kummer, D. A., Li, D., Dion, A., & Myers, A. G. (2011) · Chemical Science · doi:10.1039/c1sc00303h · Cited by 53
Corey, G. R., Stryjewski, M. E., Weyenberg, W., Yasothan, U., & Kirkpatrick, P. N. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd3051 · Cited by 53
Revised NMR assignments for rapamycin.
McAlpine, J. B., Swanson, S. J., JACKSON, M., & Whittern, D. N. (1991) · The Journal of Antibiotics · doi:10.7164/antibiotics.44.688 · Cited by 52
Walsh, T. J., Lee, J. W., Kelly, P., Bacher, J. D., Lecciones, J., Thomas, V. M., Lyman, C. A., Coleman, D. L., Gordee, R. S., & Pizzo, P. A. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.7.1321 · Cited by 50
The incretin hormones: from scientific discovery to practical therapeutics
Mudaliar, S. R. D., & Henry, R. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2561-x · Cited by 50
Frost, D. J., Brandt, K. G., Capobianco, J. O., & Goldman, R. C. (1994) · Microbiology · doi:10.1099/13500872-140-9-2239 · Cited by 49
L-671,329, a new antifungal agent. III. Structure determination.
Wichmann, C. F., Liesch, J. M., & Schwartz, R. E. (1989) · The Journal of Antibiotics · doi:10.7164/antibiotics.42.168 · Cited by 49
Biosynthetic medicinal chemistry of natural product drugs
Koehn, F. E. (2012) · MedChemComm · doi:10.1039/c2md00316c · Cited by 48
Natural product mode of action (MOA) studies: a link between natural and synthetic worlds
Clair, J. J. L. (2010) · Natural Product Reports · doi:10.1039/b909989c · Cited by 48
Fromtling, R. A., & Abruzzo, G. K. (1989) · The Journal of Antibiotics · doi:10.7164/antibiotics.42.174 · Cited by 47
The chemistry and biology of the maytansinoid antitumor agents
Kirschning, A., Harmrolfs, K., & Knobloch, T. (2008) · Comptes Rendus Chimie · doi:10.1016/j.crci.2008.02.006 · Cited by 47
From Vancomycin to Oritavancin: The Discovery and Development of a Novel Lipoglycopeptide Antibiotic
Allen, N. E. (2010) · Anti-Infective Agents · doi:10.2174/187152110790886745 · Cited by 47
Production of Novel Rapamycin Analogs by Precursor-Directed Biosynthesis
Ritacco, F. V., Graziani, E. I., Summers, M. Y., Zabriskie, T. M., Yu, K., Bernan, V. S., Carter, G. T., & Greenstein, M. D. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.4.1971-1976.2005 · Cited by 44
A Hydrogen Peroxide Based Access to Qinghaosu (Artemisinin)
Hao, H., Li, Y., Han, W., & Wu, Y. (2011) · Organic Letters · doi:10.1021/ol2015434 · Cited by 44
New agents in development for the treatment of bacterial infections
Abbanat, D., Morrow, B. J., & Bush, K. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.08.001 · Cited by 42
Rini, B. I., Kar, S., & Kirkpatrick, P. N. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2382 · Cited by 41
Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance
Nicas, T. I., Zeckel, M. L., & Braun, D. K. (1997) · Trends in Microbiology · doi:10.1016/s0966-842x(97)01051-2 · Cited by 40
The comparative effects of some phlorizin analogs on the renal reabsorption of glucose
Diedrich, D. F. (1963) · Biochimica et Biophysica Acta · doi:10.1016/0006-3002(63)91142-9 · Cited by 39
Dapagliflozin: more than just another oral glucose-lowering agent?
Katsiki, N., Παπάνας, Ν., & Mikhailidis, D. P. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.539558 · Cited by 39
Song, Y., Lunde, C. S., Benton, B. M., & Wilkinson, B. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05403-11 · Cited by 38
Discovery of micafungin (FK463): A novel antifungal drug derived from a natural product lead
Fujie, A. (2007) · Pure and Applied Chemistry · doi:10.1351/pac200779040603 · Cited by 38
Yu, M. J., Zheng, W., Seletsky, B. M., Littlefield, B. A., & Kishi, Y. (2011) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-386009-5.00013-8 · Cited by 37
Tomishima, M., Ohki, H., Yamada, A., Maki, K., & Ikeda, F. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.093 · Cited by 35
Wright, P. M., & Myers, A. G. (2011) · Tetrahedron · doi:10.1016/j.tet.2011.09.143 · Cited by 33
Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents
Washburn, W. N. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.680437 · Cited by 32
Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus
Pfister, M., Whaley, J. M., Zhang, L., & List, J. F. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.16 · Cited by 32
An Expeditious Route to Fluorinated Rapamycin Analogues by Utilising Mutasynthesis
Goss, R. J. M., Lanceron, S., Roy, A. D., Sprague, S. J., Nur-E-Alam, M., Hughes, D. L., Wilkinson, B., & Moss, S. J. (2010) · ChemBioChem · doi:10.1002/cbic.200900723 · Cited by 31
Limitations of presently available glycopeptides in the treatment of Gram-positive infection
Ziglam, H. M., & Finch, R. G. (2001) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2001.00059.x · Cited by 31
Pneumocandin DO, a new antifungal agent and potent inhibitor of Pneumocystis carinii.
Morris, S. A., SCHWARTZ, R. E., Sesin, D. F., Masurekar, P. S., HALLADA, T. C., Schmatz, D. M., Bartizal, K. F., Hensens, O. D., & Zink, D. L. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.755 · Cited by 29
Gerich, J. E., & Bastien, A. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.54 · Cited by 28
Options for the Treatment of Patients with Taxane-Refractory Metastatic Breast Cancer
Overmoyer, B. A. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.s.002 · Cited by 27
Echinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections
Holt, S. L., & Drew, R. H. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100456 · Cited by 26
van Genugten, R. E., van Raalte, D. H., & Diamant, M. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(09)70006-3 · Cited by 26
Brugaletta, S., Burzotta, F., & Sabaté, M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902837998 · Cited by 23
Collier, S. J. (1989) · Current Opinion in Immunology · doi:10.1016/0952-7915(89)90169-6 · Cited by 21
mTOR Kinase Inhibitors As A Treatment Strategy In Hematological Malignancies
Grzybowska‐Izydorczyk, O., & Smolewski, P. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.14 · Cited by 17
Synthesis of 6-thiatetracycline, a highly active analogue of the antibiotic tetracycline
Kirchlechner, R., & Rogalski, W. (1980) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)71180-4 · Cited by 16
SGLT2 Inhibitors for Type 2 Diabetes
Liu, J., & Lee, T. W. (2011) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-386009-5.00020-5 · Cited by 15
FKBP immunophilin patents for neurological disorders
Babine, R. E., Villafranca, J. E., & Gold, B. G. (2005) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.15.5.555 · Cited by 13
Coen, M. L., Lerner, C. G., Capobianco, J. O., & Goldman, R. C. (1994) · Microbiology · doi:10.1099/13500872-140-9-2229 · Cited by 13
Witting, K. F., & Süßmuth, R. D. (2011) · Current Drug Targets · doi:10.2174/138945011798109527 · Cited by 13
Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: What next?
Aftimos, P. G., & Awada, A. H. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0070-9 · Cited by 10
Partial purification of (1,3)-β-glucan synthase from Candida albicans
Frost, D. J., BRANDT, K. D., Estill, C., & Goldman, R. C. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1997.tb10202.x · Cited by 10
Totalsynthese des Anhydro‐aureomycins
Muxfeldt, H., Döpp, H., Kaufman, J. E., Schneider, J., Hansen, P. E., Sasaki, A., & Geiser, T. (1973) · Angewandte Chemie · doi:10.1002/ange.19730851110 · Cited by 10
Partial purification of (1,3)-β-glucan synthase from Candida albicans
Frost, D. J. (1997) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(96)00485-5 · Cited by 9
Role of medicines in malaria control and elimination
Warsame, M., Olumese, P. E., & Mendis, K. (2010) · Drug Development Research · doi:10.1002/ddr.20343 · Cited by 8
Antibacterial activity of a new thiatetracycline
Bakhtiar, M., & Selwyn, S. (1983) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/11.3.291 · Cited by 6
Pharmacokinetics of L-671,329 in rhesus monkeys and DBA/2 mice
Sundelof, J. G., Hajdu, R., Cleare, W. J., Onishi, J. C., & Kropp, H. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.3.607 · Cited by 6
Can New Chemistry Make a Malaria Drug Plentiful and Cheap?
Kupferschmidt, K. (2012) · Science · doi:10.1126/science.336.6083.798 · Cited by 6
Cole, P., Vicente, M., & Castaner, R. (2008) · Drugs of the Future · doi:10.1358/dof.2008.033.09.1251351 · Cited by 6
Exenatid - ein Inkretin-Mimetikum zur Behandlung des Diabetes mellitus Typ 2
Reuter, H., & Erdmann, E. (2007) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2007-970380 · Cited by 5
Neue Konzepte in der Behandlung des Typ-2-Diabetes
Meier, J. J., Schmidt, W. E., & Klein, H.-H. (2007) · Der Internist · doi:10.1007/s00108-007-1876-z · Cited by 3
Drug discovery and development: lessons from an undeveloped drug
Gordi, T. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.76 · Cited by 2
Cited by
Natural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858
Counting on natural products for drug design
Rodrigues, T., Reker, D., Schneider, P., & Schneider, G. (2016) · Nature Chemistry · doi:10.1038/nchem.2479 · Cited by 1,250
Towards the sustainable discovery and development of new antibiotics
Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., et al. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00313-1 · Cited by 1,151
Self-citationMartins, A., Vieira, H., Gaspar, H., & Santos, S. (2014) · Marine Drugs · doi:10.3390/md12021066 · Cited by 572
Green Chemistry in the Synthesis of Pharmaceuticals
Kar, S., Sanderson, H., Roy, K., Benfenati, E., & Leszczynski, J. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00631 · Cited by 566
Metadata
- Authors
- Bauer, A., & Brönstrup, M.
- Venue
- Nat. Prod. Rep.
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2014
- Volume
- 31
- Issue
- 1
- Pages
- 35-60
- ISSN
- 0265-0568 (ISSN-L)
- 1460-4752
- OpenAlex
- W2153659956
- Cited by
- 255
- References
- 302
- FWCI
- 13.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.